Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Vaccaro from our most recent announcement "Surgalign, in my opinion, is one of the most exciting, given the groundbreaking work they are doing with artificial intelligence." The relationships we have in place all important alliances and we feel we have a strong foundation to build from |
| So look, we're getting very positive feedback about how easy the system is to use and how the enhanced visualization with the AR, and it's really enhanced because of the segmentation that we use AI to generate how much easier it makes things for them because they can identify the anatomy so quickly |
| I believe this will have a very positive impact also |
| So it's been very positive |
| We've heard from larger players like HCA and [Tennant], the budgets and hiring trends have begun better and therefore helping their procedure volumes |
| I'm very proud of our execution on this front, and the team has done a remarkable job |
| We've been very fortunate, though, that revenues continued into Q1 and now even into Q2 |
| We reported Q1 2023 revenue of $16.7 million, ahead of our prior expectations |
| Along with product rationalization, we rightsized and realigned many areas of our business, and we're operating more efficiently, which has enabled us to better manage resources |
| hardware business grew by approximately $745,000 or 6.7% on a sequential basis, which was offset by a decline in international revenue of $667,000 |
| With that said, we continue to explore all strategic avenues to improve our liquidity position, including additional potential divestitures, mergers and restructurings |
| We had guided to approximately $21 million in cash on our last call for Q1, and the improvement versus our plan was driven primarily by continued reduction in operating expenses during the period |
| As for operating expenses, Q1 non-GAAP operating expense was $23 million as compared to $24.6 million in Q4, an improvement of $1.6 million sequentially |
| The improvement in our cash position is related to the sale of our Coflex business in February, which netted $14.8 million in cash to the company |
| We continue to manage our costs diligently and have removed expenses through the restructuring program with a greater impact anticipated in future periods |
| Our strategy is to align with the best of the best and gain insights into how AI can be applied in research and ultimately, how it can be leveraged in the clinical decision-making process |
| We continue to make progress on the restructuring program, and our outlook has not changed |
| The new system upgrades unveiled in March are designed to drive efficiencies and set up and workflow and support a broader range of instruments and procedures |
| And now that we're rolling out the new instruments to be able to do more types of procedures as well |
| Terry Rich Thanks, Dave, and good afternoon |
| Product rationalization programs have intensified and will continue throughout both the second and third quarters, and we've been managing distribution carefully to ensure we meet our customers' needs |
| David Lyle Thank you, and good afternoon |
| With respect to HOLO Portal, we're still seeing a long sales cycle, but discussions with many of the accounts in our pipeline are progressing well and several are in the final stages of contract negotiations |
| And as I've mentioned previously, we believe that HOLO AI Insights can be leveraged for precision medicine and apply to many different applications and population health, clinical research and in the future, patient care |
| I'm pleased to report that we currently have two new sites in the onboarding process for our upgraded system with cases scheduled in the coming quarter |
| Brian Jankowitz, a neurosurgery specialist with extensive experience in neurocritical care disorders |
| Statement |
|---|
| Once we obsoleted those products, at some point, we expect that revenue to ramp down |
| The sequential decline was driven primarily by lower revenue and gross margin somewhat offset by lower operating expense |
| Non-GAAP gross margin in Q1 was 69.5% on the higher end of our previous guidance range and down slightly sequentially compared to Q4 |
| Domestically, hospitals are still experiencing some staffing shortages and procedural delays but it hasn't been all that impact on the hardware side of our business |
| Adjusted EBITDA in Q1 was a loss of $10.8 million as compared to an adjusted EBITDA loss of $9.1 million in Q4 |
| That brings you down to $14.7 million for the first quarter, and then take out an additional $1.6 million of the products that we obsoleted in Q1 that actually still generated revenue for us |
| Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business |
| But if you take out those numbers and say, looking out into the future, what would that look like, you're talking about a number that's down to the $13 million a quarter range, just taking Q1 as a proxy |
| So it's a little harder to predict what those obsoleted products revenue contribution will be |
Please consider a small donation if you think this website provides you with relevant information